Alivus Life Sciences (BOM:543322) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543322 Alivus Life Sciences Ltd BOM:543322
83 GF Score
Price ₹1,104.05
GF Value ₹1,019.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Alivus Life Sciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Alivus Life Sciences Valuation Rank Related Terms

BOM:543322
83GF Score
Alivus Life Sciences Ltd BOM:543322
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alivus Life Sciences (BOM:543322) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,104.05 is trading 8.3% above its estimated GF Value™ of ₹1,019.60. GuruFocus considers Alivus Life Sciences to be Fairly Valued.

Key valuation signals for BOM:543322:

  • Valuation Rank:
  • GF Value™: ₹1,019.60 vs. price of ₹1,104.05 (8.3% above fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the BOM:543322 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges ALIVUS:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score

Get the complete analysis for BOM:543322

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,104.05
Price
₹1,019.60
GF Value